GenBioPro stock rises 15% within 3 months post-ruling

GenBioPro, a generic mifepristone manufacturer, will see a stock price increase of at least 15% within 90 days of the Supreme Court’s decision. The ruling removes regulatory uncertainty, boosting investor confidence in the company’s long-term viability.

Implied probability (Yes)

65%